logo
  •   Home
  • Applications
    • Indications
  • Business
  • EpiSwitch®
  • Products
    • EpiSwitch® COVID-19 Severity Test
    • EpiSwitch® Explorer Array Kit
    • EpiSwitch ® Service
  • Investors
    • Investors Overview
    • Results and Presentations
    • Share Price Information
    • Regulatory News
    • Board & Governance
    • Key Corporate Documents
    • AIM Rule 26
    • Email Alerts
    • Investor Contacts
  • News
  • About Us
    • History
    • Board of Directors
    • Management Team
    • Scientific Advisory Panel
    • Values
    • Careers
    • Contact Us

OBD launches major Diabetes epigenetics programme in Malaysia to ascertain who is at risk for Type 2 Diabetes.

April 21, 2016
|In Milestones
|By Catia Gaspar

Check out the news in The Diabetes Research & Wellness Foundation

  • Prev
  • Next

Terms of Use / Site Map / Privacy Policy / Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571
© 2002-2021 Oxford Biodynamics Plc

Privacy Preference Center

Privacy Preferences